Determination of chidamide in rat plasma by LC-MS and its application to pharmacokinetics study

Biomedical Chromatography

Volumn 27, Issue 12, 2013, Pages 1801-1806

  Wang, Xianqin ^a   Chen, Mengchun ^a   Wen, Congcong ^a   Zhang, Qingwei ^b   Ma, Jianshe ^a  

^a WENZHOU MEDICAL UNIVERSITY   (China)

^b SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY   (China)

Author keywords

Chidamide; LC MS; Pharmacokinetics; Rat plasma

Indexed keywords

BODY FLUIDS; ELECTROSPRAY IONIZATION; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; PHARMACOKINETICS; POSITIVE IONS; RATS;

CHIDAMIDE; INTERNAL STANDARDS; ITS APPLICATIONS; LC-MS; LINEZOLID; LIQUID CHROMATOGRAPHY - MASS SPECTROMETRIES; PHARMACOKINETIC STUDIES; RAT PLASMA; SELECTIVE LIQUID CHROMATOGRAPHY; STANDARD PROTEINS;

ACETONITRILE;

ANTINEOPLASTIC AGENT; CHIDAMIDE; HISTONE DEACETYLASE INHIBITOR; LINEZOLID; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CALIBRATION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DETERMINATION; ELECTROSPRAY MASS SPECTROMETRY; ION MONITORING; LIMIT OF QUANTITATION; LIQUID CHROMATOGRAPHY; MALE; MEASUREMENT PRECISION; NONHUMAN; POSITIVE ION ELECTROSPRAY; QUANTITATIVE ANALYSIS; RAT;

RATTUS;

CHIDAMIDE; LC-MS; PHARMACOKINETICS; RAT PLASMA;

AMINOPYRIDINES; ANIMALS; BENZAMIDES; CHROMATOGRAPHY, LIQUID; DRUG STABILITY; LINEAR MODELS; MALE; RATS; RATS, SPRAGUE-DAWLEY; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION;

EID: 84887153555     PISSN: 02693879     EISSN: 10990801     Source Type: Journal    
DOI: 10.1002/bmc.3001     Document Type: Article

References (29)

1. Al-Janadi A, Chandana SR and Conley BA. Histone deacetylation: an attractive target for cancer therapy? Drugs in R&D 2008; 9: 369-383.
2. Badros A, Burger AM, Philip S, Niesvizky R, Kolla SS, Goloubeva O, Harris C, Zwiebel J, Wright JJ, Espinoza-Delgado I, Baer MR, Holleran JL, Egorin MJ and Grant S. Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma. Clinical Cancer Research 2009; 15: 5250-5257.
3. Carew JS, Giles FJ and Nawrocki ST. Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy. Cancer Letters 2008; 269: 7-17.
4. Crisanti MC, Wallace AF, Kapoor V, Vandermeers F, Dowling ML, Pereira LP, Coleman K, Campling BG, Fridlender ZG, Kao GD and Albelda SM. The HDAC inhibitor panobinostat (LBH589) inhibits mesothelioma and lung cancer cells in vitro and in vivo with particular efficacy for small cell lung cancer. Molecular Cancer Therapeutics 2009; 8: 2221-2231.
5. Ferron GM, Conway WD and Jusko WJ. Lipophilic benzamide and anilide derivatives as high-performance liquid chromatography internal standards: application to sirolimus (rapamycin) determination. Journal of Chromatography. B, Biomedical Sciences and Applications 1997; 703: 243-251.
6. Ghassabian S, Moosavi SM, Valero YG, Shekar K, Fraser JF and Smith MT. High-throughput assay for simultaneous quantification of the plasma concentrations of morphine, fentanyl, midazolam and their major metabolites using automated SPE coupled to LC-MS/MS. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences 2012; 903: 126-133.
7. Gong K, Xie J, Yi H and Li WH. CS055 (Chidamide/HBI-8000), a novel histone deacetylase inhibitor, induces G(1) arrest, ROS-dependent apoptosis and differentiation in human leukaemia cells. Biochemical Journal 2012; 443: 735-746.
8. Gupta A, Singhal P, Shrivastav PS and Sanyal M. Application of a validated ultra performance liquid chromatography-tandem mass spectrometry method for the quantification of darunavir in human plasma for a bioequivalence study in Indian subjects. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences 2011; 879: 2443-2453.
9. Haberland M, Montgomery RL and Olson EN. The many roles of histone deacetylases in development and physiology: implications for disease and therapy. Nature Reviews Genetics 2009; 10: 32-42.
10. Huang XP, Gao LZ, Wang SL, Lee CK, Ordentlich P and Liu BL. HDAC Inhibitor SNDX-275 Induces Apoptosis in erbB2-Overexpressing Breast Cancer Cells via Down-regulation of erbB3 Expression. Cancer Research 2009; 69: 8403-8411.
11. Lee MJ, Kim YS, Kummar S, Giaccone G and Trepel JB. Histone deacetylase inhibitors in cancer therapy. Current Opinion in Oncology 2008; 20: 639-649.
12. Liu K, Zhong DF and Chen XY. Enantioselective determination of doxazosin in human plasma by liquid chromatography-tandem mass spectrometry using ovomucoid chiral stationary phase. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences 2010a; 878: 2415-2420.
13. Liu L, Chen BA, Qin SK, Li SY, He XM, Qiu SM, Zhao W and Zhao H. A novel histone deacetylase inhibitor Chidamide induces apoptosis of human colon cancer cells. Biochemical and Biophysical Research Communications 2010b; 392: 190-195.
14. Lu YM, Sun ZM, Zhang YF, Chen XY and Zhong DF. Simultaneous quantification of 22R and 22S epimers of budesonide in human plasma by ultra-high-performance liquid chromatography-tandem mass spectrometry: Application in a stereoselective pharmacokinetic study. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences 2013; 921: 27-34.
15. Luong QT, O'Kelly J, Braunstein GD, Hershman JM and Koeffler HP. Antitumor activity of suberoylanilide hydroxamic acid against thyroid cancer cell lines in vitro and in vivo. Clinical Cancer Research 2006; 12: 5570-5577.
16. Mai A and Altucci L. Epi-drugs to fight cancer: from chemistry to cancer treatment, the road ahead. The International Journal of Biochemistry & Cell Biology 2009; 41: 199-213.
17. Marchion D and Munster P. Development of histone deacetylase inhibitors for cancer treatment. Expert Review of Anticancer Therapy 2007; 7: 583-598.
18. Marks PA and Jiang XJ. Histone deacetylase inhibitors in programmed cell death and cancer therapy. Cell Cycle 2005; 4: 549-551.
19. Marks PA and Xu WS. Histone deacetylase inhibitors: potential in cancer therapy. Journal of Cellular Biochemistry 2009; 107: 600-608.
20. Martinez-Iglesias O, Ruiz-Llorente L, Sanchez-Martinez R, Garcia L, Zambrano A and Aranda A. Histone deacetylase inhibitors: mechanism of action and therapeutic use in cancer. Clinical and Translational Oncology 2008; 10: 395-398.
21. Mehnert JM and Kelly WK. Histone deacetylase inhibitors: biology and mechanism of action. Cancer Journal 2007; 13: 23-29.
22. Pauer LR, Olivares J, Cunningham C, Williams A, Grove W, Kraker A, Olson S and Nemunaitis J. Phase I study of oral CI-994 in combination with carboplatin and paclitaxel in the treatment of patients with advanced solid tumors. Cancer Investigation 2004; 22: 886-896.
23. Prakash S, Foster BJ, Meyer M, Wozniak A, Heilbrun LK, Flaherty L, Zalupski M, Radulovic L, Valdivieso M and LoRusso PM. Chronic oral administration of CI-994: a phase 1 study. Investigational New Drugs 2001; 19: 1-11.
24. Riva L, Blaney SM, Dauser R, Nuchtern JG, Durfee J, McGuffey L and Berg SL. Pharmacokinetics and cerebrospinal fluid penetration of CI-994 (N-acetyldinaline) in the nonhuman primate. Clinical Cancer Research 2000; 6: 994-997.
25. Song L, Morrison JJ, Botting NP and Thornalley PJ. Analysis of glucosinolates, isothiocyanates, and amine degradation products in vegetable extracts and blood plasma by LC-MS/MS. Analytical Biochemistry 2005; 347: 234-243.
26. Undevia SD, Kindler HL, Janisch L, Olson SC, Schilsky RL, Vogelzang NJ, Kimmel KA, Macek TA and Ratain MJ. A phase I study of the oral combination of CI-994, a putative histone deacetylase inhibitor, and capecitabine. Annals of Oncology 2004; 15: 1705-1711.
27. US Food and Drug Administration. Guidance for Industry - Bioanalytical Method Validation. US Department of Health and Human Services, CDER and CVM: Rockville, MD, 2001.
28. Wang HD, Deng P, Chen XY, Guo LX and Zhong DF. Development and validation of a liquid chromatography-tandem mass spectrometry method for the determination of febuxostat in human plasma. Biomedical Chromatography 2013; 27: 34-38.
29. Xu WS, Parmigiani RB and Marks PA. Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene 2007; 26: 5541-5552.